Compounds for immunotherapy of prostate cancer and methods for their use

• US 6,261,562 B1
• Filed: 02/09/1998
• Issued: 07/17/2001
• Est. Priority Date: 02/25/1997
• Status: Expired due to Fees

• Current Assignee: Corixa Corporation (GlaxoSmithKline PLC)
• Original Assignee: Corixa Corporation (GlaxoSmithKline PLC)
• Inventors: Xu, Jiangchun, Dillon, Davin C.
• Primary Examiner(s): Caputa, Anthony C.
• Assistant Examiner(s): YU, MISOOK
• Application Number:
  US09/020,956
• Time in Patent Office: 1,254 Days
• Field of Search: 530/324, 424/185.1, 514/2, 514/12
• US Class Current: 424/185.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 9/90 Isomerases (5.)

Abstract

Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive polypeptides.

Claims

1. An isolated polypeptide comprising an amino acid sequence of SEQ ID NO:

113.

2. A composition comprising the polypeptide of claim 1 and a physiologically acceptable carrier.

3. The composition of claim 2, wherein the physiologically acceptable carrier is selected from the group consisting of:

water;

saline;

alcohol;

lipids;

waxes;

buffers and microspheres.

4. A composition comprising the polypeptide of claim 1 and a non-specific immune response enhancer.

5. The composition of claim 4, wherein the non-specific immune response enhancer is selected from the group consisting of:

adjuvants;

microspheres and liposomes.

6. The composition of claim 5, wherein the adjuvant comprises a component selected from the group consisting of:

aluminum hydroxide;

mineral oil;

lipid A;

Bordella pertussis and Mycobacterium tuberculosis.

7. The composition of claim 5, wherein the adjuvant is selected from the group consisting of:

Freund'"'"'s Incomplete Adjuvant;

Freund'"'"'s Complete Adjuvant and Merck Adjuvant 65.

8. A fusion protein comprising a polypeptide according to claim 1 and a known prostate antigen.

9. A fusion protein comprising at least one polypeptide according to claim 1.

10. A composition comprising a fusion protein according to any one of claims 8 and 9, and a physiologically acceptable carrier.

11. A composition comprising a fusion protein according to any one of claims 8 and 9, and a non-specific immune response enhancer.

12. The composition of claim 11 wherein the non-specific immune response enhancer is an adjuvant.

13. A method for stimulating an immune response in a patient, comprising administering to the patient a polypeptide of claim 1.

14. A method for stimulating an immune response in a patient comprising administering a composition selected from the group consisting of:

(a) compositions comprising a polypeptide according to claim 1; and

(b) compositions comprising a fusion protein according to claim 9.